Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Protagonist Therapeutics Inc
(NQ:
PTGX
)
41.40
+0.81 (+2.00%)
Streaming Delayed Price
Updated: 3:23 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
444,194
Open
40.46
Bid (Size)
41.38 (2)
Ask (Size)
41.49 (2)
Prev. Close
40.59
Today's Range
40.10 - 41.94
52wk Range
13.72 - 42.67
Shares Outstanding
58,904,585
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
Via
ACCESSWIRE
Performance
YTD
+76.77%
+76.77%
1 Month
+9.44%
+9.44%
3 Month
+29.62%
+29.62%
6 Month
+46.65%
+46.65%
1 Year
+123.30%
+123.30%
More News
Read More
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
August 01, 2024
Via
ACCESSWIRE
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
July 31, 2024
Via
ACCESSWIRE
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Via
Benzinga
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
March 26, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
Via
ACCESSWIRE
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
July 24, 2024
Via
Benzinga
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
July 22, 2024
Via
ACCESSWIRE
3 Growth Stocks No One Is Watching (But They Should Be)
July 11, 2024
Via
InvestorPlace
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
June 28, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
June 13, 2024
Via
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
Via
ACCESSWIRE
The 3 Best Biotech Stocks to Buy in June 2024
June 05, 2024
Via
InvestorPlace
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
May 31, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
May 14, 2024
Via
ACCESSWIRE
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
May 07, 2024
Via
ACCESSWIRE
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024
From
Turnstone Biologics Corp.
Via
GlobeNewswire
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
March 18, 2024
Via
ACCESSWIRE
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
March 11, 2024
Via
ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 21, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
February 20, 2024
Via
ACCESSWIRE
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
February 07, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.